ADVM — Adverum Biotechnologies Cashflow Statement
0.000.00%
Last trade - 00:00- $94.05m
- $67.99m
- $1.00m
Annual cashflow statement for Adverum Biotechnologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -118 | -146 | -155 | -117 | -131 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 22.9 | 31.7 | 24.1 | 28.9 | 33.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 11.1 | 1.34 | 15.8 | -8.32 | 0.911 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -79.3 | -108 | -108 | -90.9 | -92.5 |
| Capital Expenditures | -11.8 | -15.1 | -11.8 | -0.808 | -0.388 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -268 | 93.8 | 154 | 97.7 | -41.5 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -280 | 78.7 | 142 | 96.9 | -41.9 |
| Financing Cash Flow Items | -2.04 | 0 | — | -0.42 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 356 | 2.4 | 0.607 | 0.069 | 120 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -3.47 | -26.7 | 34.2 | 6.04 | -14.3 |